Scarica l'app Stockscreener
3.98
2.93%
-0.12
Dopo l'orario di chiusura:
3.97
-0.010
-0.25%
Precedente Chiudi:
$4.10
Aprire:
$4.04
Volume 24 ore:
119.47K
Relative Volume:
0.58
Capitalizzazione di mercato:
$130.24M
Reddito:
$1.95M
Utile/perdita netta:
$-47.84M
Rapporto P/E:
-2.6834
EPS:
-1.4832
Flusso di cassa netto:
$-27.46M
1 W Prestazione:
-3.40%
1M Prestazione:
-16.56%
6M Prestazione:
-25.61%
1 anno Prestazione:
+32.67%
Intervallo 1D:
$3.91
$4.15
Intervallo di 1 settimana:
$3.85
$4.3213
Portata 52W:
$2.42
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.98 | 134.17M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
603.18 | 223.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.53 | 144.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
326.14 | 47.61B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
257.30 | 42.30B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
143.12 | 40.81B | 7.23B | 1.41B | 1.09B | 4.979 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire
iMDx executives are set to meet investors in New York - Stock Titan
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Insight Molecular Q2FY26 Results: Cash burn rises to $10 million - scanx.trade
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseProfit Guidance Range - vinanet.vn
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusVolatility Smirk - vinanet.vn
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - Moomoo
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
IMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - marketscreener.com
iMDx to Release Second Quarter Results on August 10, 2026 - GlobeNewswire
IMDX Rises 1.09% to $4.65 as Molecular Diagnostics Play Holds Key SupportPoint of Control - vinanet.vn
IMDX Q1 2026 Earnings: Narrower Loss Beats Consensus, Shares Gain 1.09%Earnings Seasonality - vinanet.vn
Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX - TradingView
IMDX Q2'26 Earnings: revenue estimate is 437.50K USD - TradingView
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):